Pancreatic Cancer Action Network—National Advocacy Day (June 19-20, 2017)

Pancreatic Cancer Action Network (PCAN), the leading non-profit advocacy group for pancreatic cancer patients and research, has announced its dates for their National Pancreatic Cancer Advocacy Day. The event will take place in Washington D.C., June 19-20, 2017, and represents the largest gathering of people committed to fighting the disease. In addition to raising public awareness, the event will attempt to persuade Congress to prioritize cancer research, with group meetings with elected representatives as part of the program of events.

Cellceutix’s lead oncology drug candidate, Kevetrin, is the recipient of individual FDA Orphan Drug designations for pancreatic cancer, ovarian cancer and retinoblastoma. The FDA’s Orphan Drug Designation program allows special incentives for sponsors planning to test a product for use in a rare disease or condition, defined as affecting fewer than 200,000 people in the United States. These incentives include federal grants, tax credits, and reduced filing fees during development or at the time of application for marketing approval. If eventually approved by the FDA, the product may qualify for seven years of marketing exclusivity in the United States.

Kevetrin has successfully completed a Phase 1 trial for advanced solid tumors at Dana-Farber Cancer Institute (DFCI) and Beth Israel Deaconess Medical Center.

Additional pre-clinical research on Kevetrin and its effect in ovarian cancer cell lines was recently presented at the American Association of Cancer Research (AACR) in Washington D.C., with the corresponding scientific poster available for download here. Cellceutix is currently enrolling patients in a Phase 2 trial evaluating Kevetrin in late-stage platinum-resistant Ovarian Cancer, with topline results anticipated in 4Q17. The Company is also working to develop Kevetrin as an oral anti-cancer agent.

Both pancreatic cancer and ovarian cancer are two diseases that have affected family members of the Cellceutix team directly, and is a continued reminder—on a personal level—of why Cellceutix is so committed to advancing Kevetrin and improving patient outcomes in two types of cancer that are among the world’s most deadly.

Interested parties can register to attend PCAN’s Advocacy Day by visiting the event’s registration page here.